{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:55:18Z","timestamp":1771260918670,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"Ningbo Clinical Medical Research Center for Thoracic Malignancies","award":["2021L002"],"award-info":[{"award-number":["2021L002"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]},{"name":"The Fourth Round of Ningbo Medical Key Disciplines Construction Plan","award":["2022-F03"],"award-info":[{"award-number":["2022-F03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-024-03526-w","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T01:50:11Z","timestamp":1735609811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuixin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiadi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"3526_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Cancer J Clin. 2024;74(1):12\u201349.","DOI":"10.3322\/caac.21820"},{"key":"3526_CR2","doi-asserted-by":"crossref","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A et al. Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(6):524\u2009\u2013\u200941.","DOI":"10.3322\/caac.21754"},{"key":"3526_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biology Int. 2014;2014:1\u20139.","journal-title":"Mol Biology Int"},{"issue":"3","key":"3526_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-015-3341-3","volume":"150","author":"K Kast","year":"2015","unstructured":"Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015;150(3):621\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"3526_CR5","doi-asserted-by":"crossref","unstructured":"Fernandes CL, Silva DJ, Mesquita A. Novel HER-2 targeted therapies in breast Cancer. Cancers. 2023;16(1).","DOI":"10.3390\/cancers16010087"},{"issue":"2\u20134","key":"3526_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.currproblcancer.2016.09.005","volume":"40","author":"M Soleja","year":"2016","unstructured":"Soleja M, Rimawi MF. Metastatic human epidermal growth factor receptor 2-positive breast cancer: management, challenges, and future directions. Curr Probl Cancer. 2016;40(2\u20134):117\u201329.","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"3526_CR7","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26(8):1364\u201370.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"3526_CR8","doi-asserted-by":"crossref","unstructured":"Duan F, Song C, Ma Y, Jiang K, Xu F, Bi X et al. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus. Drug design, development and therapy. 2021;15:3463-73.","DOI":"10.2147\/DDDT.S314723"},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fonc.2020.00014","volume":"10","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wang H, Sun X, Fang Y, Lu SS, Ding SN, et al. A risk stratification model for Predicting overall survival and Surgical Benefit in Triple-negative breast Cancer patients with de novo distant metastasis. Front Oncol. 2020;10:14.","journal-title":"Front Oncol"},{"issue":"14","key":"3526_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users\u2019 guides to the Medical Literature. JAMA. 2017;318(14):1377\u201384.","journal-title":"JAMA"},{"key":"3526_CR11","doi-asserted-by":"publisher","first-page":"901680","DOI":"10.3389\/fpubh.2022.901680","volume":"10","author":"Y Tong","year":"2022","unstructured":"Tong Y, Cui Y, Jiang L, Pi Y, Gong Y, Zhao D. Clinical characteristics, prognostic factor and a Novel Dynamic Prediction Model for overall survival of Elderly patients with Chondrosarcoma: a Population-based study. Front Public Health. 2022;10:901680.","journal-title":"Front Public Health"},{"issue":"18","key":"3526_CR12","doi-asserted-by":"publisher","first-page":"18597","DOI":"10.1002\/cam4.6469","volume":"12","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liang Y, Ye F, Luo D, Jin Y, Li Y, et al. Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: a retrospective study based on SEER database. Cancer Med. 2023;12(18):18597\u2013610.","journal-title":"Cancer Med"},{"issue":"4","key":"3526_CR13","doi-asserted-by":"publisher","first-page":"100232","DOI":"10.1016\/j.esmoop.2021.100232","volume":"6","author":"Y Fan","year":"2021","unstructured":"Fan Y, Wang Y, He L, Imani S, Wen Q. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival. ESMO open. 2021;6(4):100232.","journal-title":"ESMO open"},{"issue":"22","key":"3526_CR14","doi-asserted-by":"publisher","first-page":"8114","DOI":"10.1002\/cam4.4326","volume":"10","author":"X Lyu","year":"2021","unstructured":"Lyu X, Luo B. Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: a retrospective cohort study. Cancer Med. 2021;10(22):8114\u201326.","journal-title":"Cancer Med"},{"issue":"11","key":"3526_CR15","doi-asserted-by":"publisher","first-page":"e0242155","DOI":"10.1371\/journal.pone.0242155","volume":"15","author":"H Lin","year":"2020","unstructured":"Lin H, Wu Y, Liang G, Chen L. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery. PLoS ONE. 2020;15(11):e0242155.","journal-title":"PLoS ONE"},{"issue":"1","key":"3526_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091.","journal-title":"BMC Cancer"},{"issue":"2","key":"3526_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jjco\/hyq191","volume":"41","author":"M Yoshida","year":"2011","unstructured":"Yoshida M, Shimizu C, Fukutomi T, Tsuda H, Kinoshita T, Akashi-Tanaka S, et al. Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis. Jpn J Clin Oncol. 2011;41(2):180\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"3526_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1245\/ASO.2006.03.055","volume":"13","author":"K Zabicki","year":"2006","unstructured":"Zabicki K, Colbert JA, Dominguez FJ, Gadd MA, Hughes KS, Jones JL, et al. Breast cancer diagnosis in women\u2009<\u2009or =\u200940 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol. 2006;13(8):1072\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"40","key":"3526_CR19","doi-asserted-by":"publisher","first-page":"e30922","DOI":"10.1097\/MD.0000000000030922","volume":"101","author":"J Wu","year":"2022","unstructured":"Wu J, Xie Z, Xiao Y, Wang B, Zhang P. Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: a SEER-based study. Medicine. 2022;101(40):e30922.","journal-title":"Medicine"},{"issue":"4","key":"3526_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","volume":"120","author":"D Aw","year":"2007","unstructured":"Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120(4):435\u201346.","journal-title":"Immunology"},{"key":"3526_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.2009.05370.x","volume":"1197","author":"T Fulop","year":"2010","unstructured":"Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010;1197:158\u201365.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"3526_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.molonc.2014.03.022","volume":"8","author":"EM de Kruijf","year":"2014","unstructured":"de Kruijf EM, Bastiaannet E, Rubert\u00e1 F, de Craen AJ, Kuppen PJ, Smit VT, et al. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. Mol Oncol. 2014;8(5):1014\u201325.","journal-title":"Mol Oncol"},{"issue":"1","key":"3526_CR23","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1038\/s41598-023-36139-8","volume":"13","author":"S Zhu","year":"2023","unstructured":"Zhu S, Lei C. Association between marital status and all-cause mortality of patients with metastatic breast cancer: a population-based study. Sci Rep. 2023;13(1):9067.","journal-title":"Sci Rep"},{"issue":"3","key":"3526_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/pon.1394","volume":"18","author":"BM Brothers","year":"2009","unstructured":"Brothers BM, Andersen BL. Hopelessness as a predictor of depressive symptoms for breast cancer patients coping with recurrence. Psycho-oncology. 2009;18(3):267\u201375.","journal-title":"Psycho-oncology"},{"issue":"1","key":"3526_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/PSY.0000000000000261","volume":"78","author":"LC Bouchard","year":"2016","unstructured":"Bouchard LC, Antoni MH, Blomberg BB, Stagl JM, Gudenkauf LM, Jutagir DR, et al. Postsurgical depressive symptoms and proinflammatory cytokine elevations in women undergoing primary treatment for breast Cancer. Psychosom Med. 2016;78(1):26\u201337.","journal-title":"Psychosom Med"},{"issue":"11","key":"3526_CR26","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1038\/bjc.2014.174","volume":"110","author":"DA Yardley","year":"2014","unstructured":"Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756\u201364.","journal-title":"Br J Cancer"},{"issue":"1","key":"3526_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-018-4956-y","volume":"173","author":"JX Ren","year":"2019","unstructured":"Ren JX, Gong Y, Ling H, Hu X, Shao ZM. Racial\/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat. 2019;173(1):225\u201337.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3526_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-009-1190-7","volume":"66","author":"YH Park","year":"2010","unstructured":"Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol. 2010;66(3):507\u201316.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3526_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-018-4734-x","volume":"170","author":"PS Blanchette","year":"2018","unstructured":"Blanchette PS, Desautels DN, Pond GR, Bartlett JMS, Nofech-Mozes S, Yaffe MJ, et al. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Breast Cancer Res Treat. 2018;170(1):169\u201377.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"3526_CR30","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","volume":"19","author":"R Largillier","year":"2008","unstructured":"Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2008;19(12):2012\u20139.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"6","key":"3526_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines\u00ae insights: breast Cancer, Version 4.2023. J Natl Compr Cancer Network: JNCCN. 2023;21(6):594\u2013608.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"Suppl 2","key":"3526_CR32","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.breast.2007.07.008","volume":"16","author":"WC Wood","year":"2007","unstructured":"Wood WC. Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast (Edinburgh Scotland). 2007;16(Suppl 2):S63\u20136.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"6","key":"3526_CR33","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/0008-5472.CAN-03-2646","volume":"64","author":"EA Danna","year":"2004","unstructured":"Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205\u201311.","journal-title":"Cancer Res"},{"issue":"3","key":"3526_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1053\/ejso.1998.0634","volume":"25","author":"SO Hofer","year":"1999","unstructured":"Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 1999;25(3):231\u201343.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"3","key":"3526_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1010626302152","volume":"65","author":"M Retsky","year":"2001","unstructured":"Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat. 2001;65(3):217\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 3","key":"3526_CR36","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0959-8049(11)70142-3","volume":"47","author":"J Ruiterkamp","year":"2011","unstructured":"Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J cancer (Oxford England: 1990). 2011;47(Suppl 3):S6\u201322.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"11","key":"3526_CR37","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast Cancer at Presentation: protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3526_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1245\/s10434-018-6831-9","volume":"26","author":"E Pons-Tostivint","year":"2019","unstructured":"Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, et al. Survival impact of Locoregional Treatment of the primary tumor in De Novo metastatic breast cancers in a large Multicentric Cohort Study: a propensity score-matched analysis. Ann Surg Oncol. 2019;26(2):356\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"3526_CR39","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","volume":"269","author":"F Fitzal","year":"2019","unstructured":"Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, et al. Impact of breast surgery in primary metastasized breast Cancer: outcomes of the prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019;269(6):1163\u20139.","journal-title":"Ann Surg"},{"issue":"13","key":"3526_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380\u20138.","journal-title":"Lancet Oncol"},{"key":"3526_CR41","doi-asserted-by":"publisher","first-page":"103583","DOI":"10.1016\/j.breast.2023.103583","volume":"72","author":"M Di Maio","year":"2023","unstructured":"Di Maio M, Bighin C, Schettini F, Ruelle T, Marandino L, Fabi A, et al. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: data from the GIM14\/BIOMETA study. Breast (Edinburgh Scotland). 2023;72:103583.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"4","key":"3526_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"key":"3526_CR43","doi-asserted-by":"crossref","unstructured":"Yan M, Bian L, Hu XC, Zhang QY, Ouyang QC, Feng JF et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Translational Breast Cancer Res. 2020;1.","DOI":"10.21037\/tbcr-20-25"},{"issue":"3","key":"3526_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351\u201360.","journal-title":"Lancet Oncol"},{"key":"3526_CR45","doi-asserted-by":"crossref","unstructured":"Blondeaux E, Ferreira AR, Poggio F, Puglisi F, Bighin C, Sottotetti F et al. Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. ESMO open. 2020;5(4).","DOI":"10.1136\/esmoopen-2020-000719"},{"issue":"19","key":"3526_CR46","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"3526_CR47","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast Cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"key":"3526_CR48","doi-asserted-by":"crossref","unstructured":"Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Current treatment options in oncology. 2024.","DOI":"10.1007\/s11864-024-01277-2"},{"issue":"10","key":"3526_CR49","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(10):1245\u201355.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-03526-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03526-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:01:42Z","timestamp":1735614102000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-03526-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-03526-w","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the Ethics Review Board of The Affiliated Lihuili Hospital, Ningbo University, Ningbo (registration number: KY2024ML045). Informed consent was not required as the data were collected from a publicly available repository.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"675"}}